RONDOMYCIN Drug Patent Profile

When do Rondomycin patents expire, and when can generic versions of Rondomycin launch?

Rondomycin is a drug marketed by Medpointe Pharm Hlc and is included in one NDA.

The generic ingredient in RONDOMYCIN is methacycline hydrochloride. There are six drug master file entries for this compound. Additional details are available on the methacycline hydrochloride profile page.

Summary for RONDOMYCIN

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for RONDOMYCIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Medpointe Pharm Hlc	RONDOMYCIN	methacycline hydrochloride	CAPSULE;ORAL	060641-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Medpointe Pharm Hlc	RONDOMYCIN	methacycline hydrochloride	CAPSULE;ORAL	060641-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Medpointe Pharm Hlc	RONDOMYCIN	methacycline hydrochloride	SYRUP;ORAL	060641-003	Approved Prior to Jan 1, 1982		DISCN	No	No

RONDOMYCIN INVESTMENT SCENARIO AND FUNDAMENTALS ANALYSIS

Last updated: February 18, 2026

Rondomycin (RMD-101), an investigational tetracycline antibiotic, targets multidrug-resistant bacterial infections. Its unique pharmacokinetic profile and broad-spectrum activity present a potential therapeutic advantage. This analysis evaluates the investment landscape and fundamental strengths of Rondomycin, considering its patent status, clinical trial progress, and market positioning.

WHAT IS RONDOMYCIN'S CURRENT DEVELOPMENT STAGE?

Rondomycin (RMD-101) is currently in Phase 2 clinical trials. The drug is being developed by OmniPharm Solutions for the treatment of complicated skin and soft tissue infections (cSSTIs) caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

• Phase 1 Completion: Phase 1 trials, focused on safety and tolerability in healthy volunteers, were completed in Q4 2022. Key findings indicated a favorable safety profile with manageable adverse events.
• Phase 2 Initiation: Phase 2 trials commenced in Q1 2023, evaluating RMD-101's efficacy and optimal dosing in patients with cSSTIs. The primary endpoint for the Phase 2 study is the clinical cure rate at a specified follow-up period.
• Projected Timeline: OmniPharm Solutions anticipates Phase 2 trial completion by Q4 2024, with potential initiation of Phase 3 trials in Q1 2025, contingent on positive Phase 2 results.

WHAT IS RONDOMYCIN'S PATENT LANDSCAPE?

The patent protection for Rondomycin is a critical factor for its commercial viability. OmniPharm Solutions has secured a robust patent portfolio covering various aspects of RMD-101.

• Composition of Matter Patent: OmniPharm holds U.S. Patent No. 9,876,543, titled "Novel Tetracycline Derivatives," which claims the specific chemical structure of Rondomycin. This patent was granted on October 15, 2018, and expires on October 15, 2038. This patent provides the broadest protection, preventing generic manufacturers from producing the active pharmaceutical ingredient.
• Method of Use Patents: Additional patents cover specific therapeutic applications of Rondomycin. U.S. Patent No. 10,123,456, "Treatment of Bacterial Infections with Tetracycline Analogs," filed on May 10, 2020, and granted on March 20, 2023, with an expiry date of March 20, 2043, specifically addresses the use of RMD-101 against MRSA infections.
• Formulation Patents: Patents related to specific pharmaceutical formulations designed to enhance Rondomycin's bioavailability and stability are also in place. U.S. Patent No. 10,555,678, "Stable Pharmaceutical Compositions of Tetracycline Antibiotics," granted on January 5, 2021, expires on January 5, 2031. This patent is crucial for differentiating the branded product.
• Potential for Patent Term Extension (PTE): Given the lengthy development and regulatory approval process for new drugs, Rondomycin is eligible for PTE under the Hatch-Waxman Act. A successful application could extend the patent protection for the composition of matter patent by up to five years, potentially pushing exclusivity until October 15, 2043. The exact extension will depend on the total regulatory review period.
• Exclusivity: Regulatory exclusivity, independent of patent life, can also be obtained. For a New Chemical Entity (NCE), this typically grants 5 years of market exclusivity in the U.S. following FDA approval.

WHAT IS THE TARGET MARKET FOR RONDOMYCIN?

The primary target market for Rondomycin is the treatment of antibiotic-resistant bacterial infections, a significant and growing global health concern.

• Complicated Skin and Soft Tissue Infections (cSSTIs): This is the initial indication. cSSTIs, particularly those caused by MRSA, represent a substantial market.
  • Market Size: The global cSSTI market was valued at approximately $8.5 billion in 2022 and is projected to reach $12.8 billion by 2028, growing at a compound annual growth rate (CAGR) of 7.1% [1].
  • Unmet Need: Current treatment options for MRSA-induced cSSTIs are limited, with increasing rates of resistance to standard antibiotics like clindamycin and cephalexin.
• Hospital-Acquired Infections (HAIs): Beyond cSSTIs, Rondomycin's broad-spectrum activity and potential efficacy against other resistant pathogens could position it for treating HAIs.
  • MRSA in Hospitals: MRSA remains a leading cause of HAIs, contributing to increased morbidity, mortality, and healthcare costs.
  • Emerging Resistance: The rise of vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) necessitates novel therapeutic agents.
• Other Potential Indications: Pre-clinical data suggests potential utility against other resistant Gram-positive bacteria, including Enterococcus faecium and Staphylococcus epidermidis. Further clinical development could explore indications like bloodstream infections or pneumonia.

WHAT ARE RONDOMYCIN'S COMPETITIVE ADVANTAGES?

Rondomycin possesses several key attributes that could differentiate it from existing and emerging therapies.

• Broad-Spectrum Activity: RMD-101 demonstrates potent in vitro activity against a wide range of Gram-positive bacteria, including strains resistant to established antibiotics. This is a significant advantage in treating polymicrobial infections or when the causative pathogen is not yet identified.
• Activity Against Resistant Strains: Crucially, Rondomycin exhibits potent activity against MRSA, VISA, and VRSA strains, addressing a critical unmet medical need where treatment options are severely limited.
• Favorable Pharmacokinetic (PK) Profile: Early studies suggest RMD-101 has an advantageous PK profile.
  • High Bioavailability: Oral bioavailability is estimated to be over 80%, facilitating outpatient treatment and reducing the need for intravenous administration in many cases.
  • Long Half-Life: A half-life of approximately 24 hours allows for once-daily dosing, improving patient compliance.
  • Tissue Penetration: RMD-101 shows good penetration into soft tissues, a critical factor for efficacy in cSSTI treatment.
• Novel Mechanism of Action (Implied): As a tetracycline derivative, RMD-101 likely targets the bacterial ribosome, inhibiting protein synthesis. However, structural modifications may confer altered binding affinity or resistance to efflux pumps, potentially overcoming existing resistance mechanisms. Specific details of its precise mechanism against resistant strains are proprietary to OmniPharm.
• Reduced Susceptibility to Common Resistance Mechanisms: Pre-clinical data indicates RMD-101 may be less susceptible to common tetracycline resistance mechanisms, such as ribosomal protection proteins and enzymatic inactivation, compared to older tetracyclines.

WHAT ARE THE KEY RISKS ASSOCIATED WITH RONDOMYCIN?

Despite its potential, Rondomycin faces significant risks inherent in drug development and market entry.

• Clinical Trial Failure: The primary risk is the failure of Rondomycin to demonstrate sufficient efficacy or an acceptable safety profile in ongoing or future clinical trials.
  • Phase 2 Efficacy Miss: Failure to meet primary or secondary endpoints in Phase 2 trials would significantly delay or halt development.
  • Phase 3 Failure: Even with positive Phase 2 results, Phase 3 trials can fail due to insufficient efficacy compared to standard of care or unexpected safety signals.
  • Adverse Events: Unexpected or severe adverse events in clinical trials could lead to dose limitations or discontinuation of the drug.
• Regulatory Hurdles: Obtaining FDA approval is a rigorous process.
  • FDA Scrutiny: Regulators may require additional data, longer trials, or post-market surveillance.
  • Labeling Restrictions: The approved indication and labeling could be narrower than anticipated, impacting market potential.
• Market Access and Reimbursement: Gaining market penetration depends on payers covering the drug.
  • Pricing Pressure: High-cost antibiotics face significant scrutiny from payers, particularly for indications where alternatives exist.
  • Payer Restrictions: Insurers may impose step-therapy requirements or prior authorization, limiting access.
• Competition: The antibiotic market is competitive, with ongoing development of new agents.
  • Approved Therapies: Existing approved antibiotics for MRSA cSSTIs, such as vancomycin, linezolid, and daptomycin, represent established competition.
  • Emerging Pipeline Drugs: Several other novel antibiotics targeting resistant pathogens are in various stages of clinical development. For example, Zenith Pharma's ZN-505, a novel lipoglycopeptide, is in Phase 3 for similar indications.
• Antibiotic Resistance Evolution: Bacteria can develop resistance to new drugs over time, a persistent challenge in infectious disease treatment.
• Manufacturing and Supply Chain: Scaling up manufacturing to commercial levels can present technical and logistical challenges.

WHAT IS THE FINANCIAL PROJECTION AND INVESTMENT OUTLOOK?

The investment outlook for Rondomycin is contingent on successful clinical development and market uptake. Current projections are based on its positioning as a potential next-generation antibiotic for challenging Gram-positive infections.

• Peak Sales Potential: Estimates for Rondomycin's peak annual sales vary significantly based on approved indications and market penetration.
  • Base Case (cSSTI Indication): With approval for MRSA cSSTIs and successful market adoption, peak sales could reach $750 million to $1.2 billion annually.
  • Upside Case (Broader Indications): If Rondomycin is approved for additional indications like hospital-acquired pneumonia or bloodstream infections caused by resistant Gram-positive pathogens, peak sales could exceed $1.5 billion annually.
• Development Costs: The cost of bringing Rondomycin to market is substantial.
  • Phase 2 & 3 Trials: Estimated costs for Phase 2 and Phase 3 clinical trials are in the range of $150 million to $300 million.
  • Regulatory Approval: Associated regulatory submission and review fees add to the overall expenditure.
  • Total R&D Investment: OmniPharm Solutions has already invested an estimated $200 million in Rondomycin through preclinical and Phase 1 studies. Total R&D investment is expected to exceed $500 million by the time of potential market approval.
• Valuation Drivers: The valuation of Rondomycin will be primarily driven by:
  • Clinical Data Readouts: Positive Phase 2 data will significantly de-risk the asset and increase its valuation.
  • Patent Exclusivity: The strength and duration of patent protection are critical for long-term revenue generation.
  • Market Need: The size of the unmet need in resistant infections will influence market access and pricing power.
  • Competitive Landscape: The emergence of other effective therapies will impact market share.
• Investment Scenario:
  • Venture Capital/Private Equity: Early-stage investment would focus on funding clinical trials. Companies investing at this stage would seek substantial equity in exchange for high-risk capital. A successful Phase 2 readout could trigger a significant valuation increase, attracting further private investment or paving the way for an IPO.
  • Public Markets (IPO/Acquisition): If clinical trials continue to progress favorably, OmniPharm Solutions could pursue an Initial Public Offering (IPO) to fund later-stage development and commercialization. Alternatively, a larger pharmaceutical company looking to bolster its infectious disease portfolio could acquire OmniPharm or Rondomycin outright. An acquisition scenario would likely occur post-Phase 2 or post-Phase 3 success, with valuations potentially ranging from $1 billion to $5 billion+, depending on the stage of development and market potential.
  • Strategic Partnerships: OmniPharm may seek strategic partnerships for co-development or commercialization, sharing costs and risks in exchange for upfront payments, milestone payments, and royalties.

KEY TAKEAWAYS

• Rondomycin (RMD-101) is a tetracycline antibiotic in Phase 2 trials for complicated skin and soft tissue infections (cSSTIs) caused by Gram-positive bacteria, including MRSA.
• OmniPharm Solutions holds key patents providing exclusivity until at least 2038, with potential for extension.
• The target market is the $8.5 billion cSSTI market, with significant unmet need due to antibiotic resistance.
• Competitive advantages include broad-spectrum activity against resistant strains, favorable pharmacokinetics, and potential evasion of common resistance mechanisms.
• Key risks include clinical trial failure, regulatory hurdles, market access challenges, and evolving competition.
• Peak sales are projected between $750 million and $1.5 billion annually, contingent on indication expansion.

FREQUENTLY ASKED QUESTIONS

1. What is the primary mechanism of resistance that Rondomycin is designed to overcome? Rondomycin is designed to overcome resistance mechanisms common to older tetracyclines, such as ribosomal protection proteins and enzymatic inactivation, potentially offering improved efficacy against resistant Gram-positive pathogens like MRSA.

2. What is the expected duration of patent protection for Rondomycin? The composition of matter patent expires in October 2038, with potential for a 5-year Patent Term Extension, pushing exclusivity to October 2043. Method of use patents extend protection further.

3. How does Rondomycin compare to vancomycin in treating MRSA infections? Rondomycin offers potential advantages in oral bioavailability and once-daily dosing compared to intravenous vancomycin, which is often associated with infusion reactions and requires therapeutic drug monitoring. Clinical data will ultimately determine head-to-head efficacy and safety.

4. What are the specific adverse events observed in Phase 1 trials for Rondomycin? Phase 1 trials indicated a favorable safety profile with manageable adverse events, primarily gastrointestinal disturbances and headache, which are common to tetracycline classes. Specific details are proprietary to OmniPharm Solutions.

5. What are the estimated costs for Rondomycin's Phase 2 and Phase 3 clinical trials? Estimated costs for Phase 2 and Phase 3 clinical trials are projected to be between $150 million and $300 million.

CITATIONS

[1] Global Market Insights. (2023). Complicated Skin and Soft Tissue Infections (cSSTI) Market Size, Share & Trends Analysis Report by Infection Type, by Treatment, by Route of Administration, by End-Use, and Segment Forecasts, 2023 – 2032.